医学
无容量
免疫组织化学
生物标志物
肿瘤科
活检
肺癌
内科学
临床终点
预测值
肺
生存分析
癌症
预测标记
阶段(地层学)
病理
试验预测值
无进展生存期
总体生存率
前瞻性队列研究
实体瘤疗效评价标准
PD-L1
标准摄取值
临床试验
组织微阵列
免疫疗法
金标准(测试)
作者
Frank Johannes Borm,Jasper N. Smit,Nienke R. Gerards,Sanne E. Wiegers,V. van devan der Noort,Yihzi Wang,Danielle Cohen,Kim Monkhorst,Diederik J. Grootendorst,David Leung,Ronald Boellaard,Egbert Frederik Smit,Adrianus Johannes De Langen
出处
期刊:Journal of nuclear medicine
[Society of Nuclear Medicine and Molecular Imaging]
日期:2026-10-29
卷期号:: jnumed.126.272588-jnumed.126.272588
标识
DOI:10.2967/jnumed.126.272588
摘要
Programmed death ligand 1 (PD-L1) immunohistochemistry, the current standard biomarker for predicting response to programmed death protein 1/PD-L1 checkpoint inhibitors in non–small cell lung cancer, has moderate predictive value among others because of tumor heterogeneity and limited biopsy representation, whereas PD-L1 PET/CT using 18F-BMS-986192 enables noninvasive, whole-tumor assessment of PD-L1 expression and heterogeneity, potentially improving prediction of response to immunotherapy. Methods: In this prospective multicenter biomarker exploration study, patients with stage IV non–small cell lung cancer eligible for nivolumab-based therapies underwent baseline 18F-BMS-986192 PET/CT, 18F-FDG PET/CT, and tumor biopsy for PD-L1 immunohistochemistry before treatment initiation. The primary endpoint was durable clinical benefit, defined as progression-free survival (PFS) of 9 mo or greater, with secondary analyses assessing associations among tracer uptake, PD-L1 expression, survival outcomes, and PET-based radiomic features. Results: Of 91 enrolled patients, 77 were included in the final analysis of 18F-BMS-986192 PET/CT. Although PD-L1 immunohistochemistry did not differ between patients with PFS of less than 9 mo versus 9 mo or greater, PD-L1 PET uptake in lung lesions was significantly higher in patients with PFS of at least 9 mo (P = 0.01). Using an optimal mean SUVpeak cutoff of 2.4, PD-L1 PET demonstrated a high negative predictive value (94%) for durable clinical benefit, with significant associations for both PFS and overall survival, particularly in patients receiving first-line treatment. Tracer uptake showed no correlation with 18F-FDG uptake. Conclusion:18F-BMS-986192 PET/CT revealed interpatient PD-L1 variability. Low uptake in lung lesions predicted poor outcomes with high negative predictive value. 18F-BMS-986192 PET/CT demonstrated stronger negative predictive value than did baseline PD-L1 immunohistochemistry in this cohort. These findings require prospective validation.
科研通智能强力驱动
Strongly Powered by AbleSci AI